Fundamental policy and growth strategy overview


The results of 2017-2020 mid-term management plan were as follows.


Except shareholder returns, fell short of target management indicators, partly due to the transfer of the pharmaceuticals business and the impact of COVID-19.
Although challenges remain to turn a profit in overseas operations, we achieved several positive results including a wider brand awareness and customer base, overseas development for POLA, progress in rebranding ORBIS and the creation of new brands.